This phase III clinical trial was conducted to evaluate the immunogenicity and safety of the single-dose and multi-dose formulations of a novel MMR vaccine (live, freeze-dried) developed by M/s Cadila Healthcare Limited, India (Cadila MMR vaccine), containing the Hoshino mumps strain, compared to that of an existing MMR vaccine (live, freeze-dried) developed by M/s Serum Institute of India Limi...

background mumps, measles and rubella viruses lead to various kinds of complica- tions such as meningoencephalitis, deafness, congenital abnormalities and even cause mortality in malnourished patients,. since 2004, mmr vaccination in two series of one year of age and four to six years has been administered to iranian children as a part of routine vaccination program. recently, mmr vaccination s...

Measles, mumps, and rubella vaccine carries a risk of joint symptoms particularly in children under 5 years. A boy who presented with an inflamed knee after measles and mumps vaccination is reported; synovial fluid aspirated from the joint contained 4.3 x 10(9)/l leucocytes. It is thought that the mumps component is the aetiological cause of acute monoarthritis.

Received October 4, 2002 Abstract There has been long standing concern about the safety of measles-mumps-rubella vaccine in children with history of egg allergy. We review our experience in vaccinating such children in our hospital over a fouryear period. Clinical evidences on the risk of anaphylactic reaction after measles-mumps-rubella vaccination is reviewed. A revised recommendation for the...

OBJECTIVE This study (NCT00969436) compared the immunogenicity and safety of measles-mumps-rubella (MMR) followed by MMR+varicella (V) vaccines to (1) 2 doses of combined MMRV and (2) MMR followed by MMRV, in Indian children. DESIGN Phase III, open, randomised, non-inferiority study. SETTING 6 tertiary care hospitals located in India. PARTICIPANTS Healthy participants aged 9-10 months not...

Before the introduction of measles, mumps, and rubella vaccine a survey was carried out to measure antibody prevalence to the three viruses by age. A total of 8716 samples of serum collected by five public health laboratories in different parts of England during 1986-7 were tested. Despite the current measles vaccination programme 60% of children aged 1-2 years did not have measles antibody and...

OBJECTIVE The policy of administering the second dose of measles-mumps-rubella (MMR) vaccine (MMR(2)) has recently changed in Iran, at age 1.5 years instead of 4-6 years previously. The effects of such a change on the immune status of the individual are evaluated in this study. METHODS Totally 249 and 228 children aged 18 months and 4- to 6-year-olds, respectively, with a documented receipt o...

AIM To identify factors associated with non-uptake of preschool booster immunisation. DESIGN Data from the computerised child health system was used to study all children born in 1990 and living in South Glamorgan, Wales, on their 5th birthday. Factors associated with preschool booster uptake were investigated using multiple logistic regression. RESULTS Preschool booster coverage in the stu...

In countries where routine varicella vaccination is implemented, it is usually given at the same age as that recommended for measles-mumps-rubella (MMR) vaccination. A combined multivalent measles-mumps-rubella-varicella (MMRV) vaccine would offer the convenience of a single injection and facilitate implementation of varicella vaccination into routine childhood immunisation schedules. We evalua...

BACKGROUND The reported coverage of the measles-rubella (MR) or measles-mumps-rubella (MMR) vaccine is greater than 99.0% in Zhejiang province. However, the incidence of measles, mumps, and rubella remains high. In this study, we assessed MMR seropositivity and disease distribution by age on the basis of the current vaccination program, wherein the first dose of MR is administered at 8 months a...